343 results on '"Odia, Yazmin"'
Search Results
2. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
3. DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets
4. An Update on H3K27M-altered Diffuse Midline Glioma: Diagnostic and Therapeutic Challenges in Clinical Practice
5. Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases
6. Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance
7. Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States
8. Contemporary Neuroscience Core Curriculum for Medical Schools
9. Surgically targeted radiation therapy (STaRT) for recurrent brain metastases: Initial clinical experience
10. Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance.
11. Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis
12. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
13. Treatment of glioblastoma using MRIdian® A3i BrainTx™: Imaging and treatment workflow demonstration
14. Comparative evaluation of the diagnostic and prognostic performance of CNSide™ versus standard cytology for leptomeningeal disease
15. Urgent Caesarean Section Followed by Tumor Resection for Pregnancy-related Rapid Growth of WHO Grade 1 Pilocytic Astrocytoma (P4-5.021)
16. Relationship between insurance status and interhospital transfers among cancer patients in the United States
17. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
18. Lumican, pro-tumorigenic or anti-tumorigenic: A conundrum
19. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
20. Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
21. An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
22. Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon
23. Table S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
24. Supplementary Figures 1-15 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
25. Supplementary Data S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
26. TMET-02. CLINICAL EFFICACY OF ONC201 IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS IS DRIVEN BY DISRUPTION OF INTEGRATED METABOLIC AND EPIGENETIC PATHWAYS
27. Data from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
28. PATH-01. COMPARATIVE EVALUATION OF THE DIAGNOSTIC AND PROGNOSTIC PERFORMANCE OF CNSIDE™ VERSUS STANDARD CYTOLOGY FOR LEPTOMENINGEAL DISEASE
29. Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1–Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome
30. Hospitalization rates for complications due to systemic therapy in the United States
31. Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational Study
32. Early imaging marker of progressing glioblastoma: a window of opportunity
33. An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
34. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
35. P001 / #307 - THE BEST OF BOTH WORLDS: COMBINED PROTON-PHOTON RADIOTHERAPY FOR DIFFICULT-TO-TREAT SKULL BASE AND SPINE TUMORS
36. O145 / #479 - POST-RADIOTHERAPY NEUROCOGNITIVE FUNCTION EVALUATION IN PRIMARY BRAIN TUMOR PATIENTS ON A PROSPECTIVE OBSERVATIONAL STUDY UTILIZING A MULTI-DIMENSIONAL APP-BASED ASSESSMENT TOOL
37. O144 / #358 - BRAIN SUBSTRUCTURE ATROPHY IS ASSOCIATED WITH RADIATION DOSE AND NEUROCOGNITIVE OUTCOMES TWO YEARS FOLLOWING PROTON THERAPY: A PROSPECTIVE LONGITUDINAL TRIAL
38. Inpatient Palliative Care Use Among Critically Ill Brain Metastasis Patients in the United States
39. Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon.
40. EBV-positive primary CNS lymphoma restricted to the conus medullaris in an immunocompetent host
41. Key Clinical Principles in the Management of Glioblastoma
42. Core curriculum guidelines for a required clinical neurology experience
43. Erratum to: Stereotactic targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review
44. Trial in Progress: Zanubrutinib with Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial with a Safety Lead-in
45. Surgically targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review
46. CTNI-61. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA
47. CTIM-20. PROSPECTIVE RANDOMIZED PHASE II PLACEBO-CONTROLLED TRIAL OF SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA (SURVIVE)
48. SYST-14 CLINICAL EFFICACY OF ONC201 IN RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA (DMG) PATIENTS
49. SYST-07 WINDOW-OF-OPPORTUNITY STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND THALAMIC GLIOMA
50. A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.